Recognized as a pioneer
on the TIME100 Most Influential Companies list, Qure.ai is using AI to reshape
access and diagnosis of high-burden diseases worldwide.
Back
Qure.ai, the world’s most
widely adopted digital health innovator, has been
named to TIME’s 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights
companies making an extraordinary global impact through innovation, ambition,
and measurable success.
TIME’s editorial
spotlighted Qure.ai’s work in advancing diagnostic equity through AI, stating: “Trained on one of the world’s largest
data sets, Qure.ai’s algorithms are as accurate as a radiologist, according to
the company, providing crucial insights in rural or developing areas where
specialists may not be available. Qure.ai tools have now been deployed in more
than 100 countries, and the company has 18 FDA clearances—the greatest number
for lung cancer AI in the U.S.—including three new approvals in 2024.”
Qure.ai was selected
alongside iconic and dynamic brands such as Abbott, Midi Health, Vertex
Pharmaceuticals, Function Health, Gilead, CRISPR Therapeutics, NBBJ, and
Northwell Health, and is featured in the Pioneer category among health tech AI
firms on the 2025 list.
Speaking on the recognition, Prashant
Warier, CEO and Founder said, “To be named among TIME’s 100 Most
Influential Companies is an acknowledgment of a simple but urgent belief: that
access to timely, high-quality diagnostics should not depend on where you live.
This honor reflects the dedication of our teams and partners across continents,
working to close the gap between innovation and impact. This recognition pushes
us to keep advancing that future, where care begins long before crisis.”
This milestone recognition
follows a pivotal year for Qure.ai, marked by accelerated momentum in the
United States. With over 18 FDA-cleared findings and the launch of its Lung
Cancer Care Continuum, a portfolio of AI solutions to detect, measure, and manage
lung nodules; Qure.ai now offers an end-to-end suite that supports earlier lung
cancer diagnosis across diverse care settings. Backed by a strategic Series D
round led by global investors including Lightspeed, 360 One Asset, and the
Merck Global Health Innovation Fund, the company is scaling its commercial and
clinical impact worldwide.
On the global front, Qure.ai
continues to lead in innovation for low- and middle-income countries, drawing
on its deep experience in TB surveillance at scale. Its newest offering, Aira, a
multi-disease clinical AI co-pilot, was launched at the World Health Assembly
in Geneva to support care coordination in resource-constrained settings.
To compile this year’s
TIME100 list, TIME’s editors evaluated nominees across sectors based on impact,
innovation, ambition, and success, after polling its global network of
journalists and outside experts. The final list spotlights 105 companies
helping chart a path forward for the world.
See the full list here: https://time.com/collections/time100-companies-2025/7289652/qure-ai/?filters=pioneers
